UroVysion, urine cytology, and the College of American Pathologists: where should we go from here?
Abstract
Abstract UroVysion (Abbott Molecular Inc, Des Plaines, Illinois) is a US Food and Drug Administration-approved test for the diagnosis of urothelial carcinoma. Although widely used, there are a variety of different ways to evaluate and interpret the test, and questions remain about the test's cost effectiveness and reproducibility in actual clinical practice. I suggest that the College of American Pathologists has a unique opportunity to create educational programs focusing on borderline or difficult urine cytology and UroVysion samples to provide data upon which to make evidence-based decisions concerning the best use of these tests.
我要评论
本期排行
- Comparison of 10 indirect fluo...
- Basaloid follicular hamartoma.
- Significance of high-risk huma...
- A practical approach to testic...
- Comparison of ThinPrep prepara...
- PAX-2 is a helpful marker for ...
- Low-grade papillary urothelial...
- Interference of hawthorn on se...
- Challenges and opportunities i...
- UroVysion, urine cytology, and...
共0条评论